NCT05611645View on ClinicalTrials.gov

Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
GliomaRecurrent Glioma
Interventions
RADIATION

Hypofractionated Stereotactic Radiotherapy

Starting with low-dose bevacizumab, 25Gy in 5 fractions of 5 Gy each delivered on consecutive treatment days.

DRUG

Bevacizumab

Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.

Trial Locations (1)

200040

CyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai

All Listed Sponsors
lead

Huashan Hospital

OTHER